<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Elise Jenkins on Medium]]></title>
        <description><![CDATA[Stories by Elise Jenkins on Medium]]></description>
        <link>https://medium.com/@elisejenkins17?source=rss-d5a04e17b9ac------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*wKHnTZ52MTRZVRJ-</url>
            <title>Stories by Elise Jenkins on Medium</title>
            <link>https://medium.com/@elisejenkins17?source=rss-d5a04e17b9ac------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 13:53:53 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@elisejenkins17/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Cancer sucks]]></title>
            <link>https://medium.com/@elisejenkins17/cancer-sucks-36e2b0c394ff?source=rss-d5a04e17b9ac------2</link>
            <guid isPermaLink="false">https://medium.com/p/36e2b0c394ff</guid>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[brain]]></category>
            <category><![CDATA[bci]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Elise Jenkins]]></dc:creator>
            <pubDate>Wed, 30 Oct 2024 14:40:35 GMT</pubDate>
            <atom:updated>2024-10-30T15:19:12.875Z</atom:updated>
            <content:encoded><![CDATA[<p>We live in a time where a conversation about cancer quickly becomes: “my uncle has..”, “my best friend has..”, “my sister has..” and even “I have..” cancer.</p><p>People tend to think cancer is age discriminating or “an old person’s” disease. The reality is so far from this. There has been a 79.1% increase of the incidence of early-onset (&lt;50 years) cancers since 1990[1]. More often than I am comfortable to admit, young people are being diagnosed.</p><h3>In the U.K over 1000 people will receive a cancer diagnosis today. In the U.S, it’s over 5000 each day.</h3><p><em>Cancer really sucks.</em></p><p>For a disease that is so prevalent and can affect people of any demographic, it is astonishing to me that we still know very little about how it progresses over time. We rely on snapshot monitoring methods to tell us an incredibly complex story. We treat based on this information, because it’s the best that can be done within the short decision times that healthcare experts have available to them. We wait until the next routine (or non-routine) visit or for symptoms to worsen before intervening or changing treatment because there is no better option available. Cancer diagnosis (mostly) and treatment today is <em>reactive</em>.</p><h3>It is not enough.</h3><p>To date, there is not a single method available to understand disease evolution, longitudinally, in a natural environment. There are close to zero clinically available true “precision medicine” approaches where we take all unique factors of a person into consideration when treating. We know that disease evolves, sometimes very fast, it spreads, and it kills. We know that diseases vary person to person, yet we throw a blanket and hope to cover as many grounds as possible, at the cost of life quality.</p><p>During my PhD at the University of Cambridge, I began researching brain tumours, particularly Glioblastoma. I learnt of its absolute devastation, and that there hasn’t been a single breakthrough that has changed the standard of care in over 20 years.</p><h3>Engineers are problem solvers</h3><p>I came from an electrical engineering background. Engineers are problem solvers (sometimes to a fault). I set out on a personal mission to solve to this problem and became truly <em>obsessed</em>.</p><p>I learnt that in this disease, <strong>50% of people were automatically non-responders</strong> to the primary interventional drug (temozolomide)[2]. I learnt that surgical resection, of which 77% of people undergo, was the <strong>highest contributing factor to overall survival</strong> (the more debulked, the better). However there is a careful tradeoff for maximum resection and the resultant neurological quality[3]. I learnt that the diseased cells were of a lineage that many people studied in neuroscience. I learnt that <strong>not only is this disease electrically active</strong>, but communicates with the rest of the brain (particularly neurons)[4][5][6].</p><p>I worked alongside several incredible researchers in the <a href="https://bioelectronics.eng.cam.ac.uk/">bioelectronics lab</a> who developed neurotechnologies — methods of reading and writing the nervous system to harness and control its function.</p><p>After spending years in the lab taking neuroscience and neurotechnology approaches and applying them to cancer, I approached my now co-founder with the idea to<strong> develop the first implantable brain-computer interface (BCI) to track and treat cancer</strong>. In 2022, <a href="https://www.opto.bio/">we raised</a> a pre-seed round, recruited an outstanding and diverse team, validated an MVP — the world’s smallest and first <strong>MRI transparent BCI platform</strong> — and demonstrated that this platform can both measure cancer progression biomarkers longitudinally in realtime and modulate brain function to quieten cancerous signalling. We are so excited to share our results which are in preparation for publication (with our remarkable collaborators).</p><p>Our aim is to translate our platform to first human trials in the next 2 years, showcasing the utility of our tiny yet powerful BCI in a dramatically underserved vertical. For the first time in history, we will have longitudinal data, which will indicate not just how, but when disease evolves, when it does/doesn’t respond to drugs and where it is spreading, all while providing a continuous, complimentary therapy to the standard of care.</p><blockquote>When we founded <a href="https://www.opto.bio/">Opto</a>, we made it our sole mission to take all the lessons from neuroscience and neurotechnology and apply them to cancer — developing the first BCI platform that can measure cancer progression and modulate nervous system function to suppress growth.</blockquote><p>We now know that these scientific and technical underpinnings <strong>extend beyond the brain</strong>, and we have started discovery and pre-clinical work on pancreatic cancer, our first follow on disease.</p><p>Follow our progress as we share our findings through academic publishing and other media platforms.</p><p><strong>References (all open access):</strong></p><p>[1] <a href="https://bmjoncology.bmj.com/content/2/1/e000049">https://bmjoncology.bmj.com/content/2/1/e000049</a></p><p>[2] <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6150109/">https://pmc.ncbi.nlm.nih.gov/articles/PMC6150109/</a></p><p>[3] <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6438173/">https://pmc.ncbi.nlm.nih.gov/articles/PMC6438173/</a></p><p>[4] <a href="https://www.nature.com/articles/nrc3129.pdf">https://www.nature.com/articles/nrc3129.pdf</a></p><p>[5] <a href="https://www.nature.com/articles/s41586-023-06036-1">https://www.nature.com/articles/s41586-023-06036-1</a></p><p>[6] <a href="https://www.nature.com/articles/s41586-019-1563-y">https://www.nature.com/articles/s41586-019-1563-y</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=36e2b0c394ff" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>